The firm brings unique experience to tracking, assessing and explaining regulatory and reimbursement policy that affect the biopharmaceutical industry. The company’s goal is to advance mutual understanding among policymakers, business executives and the investment community, in the belief that a deeper understanding of policy leads to better business, and a deeper understanding of business leads to better policy.
Member Sign In:
- Advisory Committee Tracker: Novartis Oncology Drug, Rockwell Iron Replacement Therapy Face Tough Test At ODAC Oct. 30, 2014
- Adaptive Licensing in the US: EU Pilot Project, FDA Animal Drug Process Offer Potential Models For Upcoming Legislation Oct. 28, 2014
- Daiichi Edoxaban For Atrial Fib: “Non-Inferiority” May Not Be Good Enough, But Approval For Renally Impaired Likely Oct. 28, 2014
See More Research Notes